Sitemap

Pages

• About
  • History
  • Leadership Team
    • Donna Kato
    • Elizabeth Narciso
    • Ken Phelps
    • Kristi Miller, Ph.D.
    • Robb Lawrence
    • Ruth Stevens
    • Sameena Sharif, Ph.D.
    • Scott Cain
    • Shari Medendorp, MPH
    • Willette Jones Whitmore, CCRP
  • Locations
  • Our Approach
  • Senior Consultants
    • Aurora Sosa, M.A.
    • Bill Stoltman
    • Brian Masters, Ph.D
    • Catherine Gatza
    • Chris Hendry
    • Fedra Molaie-Holagh
    • Galina Bernstein
    • Irene Figari
    • Jason McEwan
    • Laura Kilgore, RAC
    • Naomi Kautz, M.S.
    • Olu Aloba
    • Stacey Ayres
• Careers
• Considerations for Oncology Development Video
• Contact
• Home
• Join Premier Partners
• Resources
  • Blog
  • Case Studies
    • Multidisciplinary Team Advances Immuno-Oncology Development
  • Events
  • Guides and Checklists
    • Succeeding with the FDA: Answers to Seven Common Questions About IND Submissions
  • Media
    • PharmaLive: Advancing Gene Therapy Development
    • Premier Research Launches Premier Consulting Business Unit
  • Webinars
    • 505(b)(2) Regulatory Planning: Creating Value for Patients and Sponsors
    • Achieving Long-Term Success for Your Development Program — Mark McCamish
    • Achieving Long-Term Success for Your Development Program — Mike Dial and Tim Sullivan
    • Challenges and Opportunities in Rare Pediatric Drug Development
    • How Commercial Insights Can be Used to Maximize an Early Exit
    • Let’s Get Real: The Growing Importance of RWD and RWE in Regulatory Decision-Making
    • Leveraging the Target Product Profile (TPP) to Maximize Breakthrough Potential
    • New Drug Development: Succeeding With the FDA
    • The Pediatric Research Equity Act (PREA) and Its Implications for Oncology Development
  • What is 505(b)(2)?
  • Whitepapers
    • Assembling the Right Team for a Successful Nonclinical Program
      • Thank You – Assembling a Nonclinical Team White Paper
    • Beginning With The Rare Disease Patient In Mind: 6 Ways to Accommodate the True Rare Disease Patient Journey
      • Thank You – Beginning With the Patient in Mind White Paper
    • FDA Designations for Rare Disease Products: A Complete Guide to Orphan Drug, Rare Pediatric Disease, and Humanitarian Use Device Designations
      • Thank You – Rare Disease Designations White Paper
    • Identifying Products for Drug Development Programs
    • Understanding New FDA Guidance For Pediatric Oncology Studies: A Sponsor’s Guide to the FDA Research to Accelerate Cures and Equity for Children Act
      • Thank You – FDA Guidance For Pediatric Oncology Studies White Paper
    • Understanding the 505(b)(2) Approval Pathway
      • Thank You – 505(b)(2) Approval Pathway White Paper
• Solutions
  • Clinical & PK Services
  • CMC Services
  • Commercial Strategy
  • Drug Development Strategy
  • Electronic Publishing (eCTD)
  • Electronic Trial Master Files
  • Medical & Regulatory Writing
  • Nonclinical Services
  • Premier Partners
  • Project Management
  • Quality Assurance
  • Regulatory Services & Support
• Terms of Use